

Cerecin Presents New Data on *Tricaprilin* at Alzheimer's Association International Conference 2020

New formulation of tricaprilin, AC-SD-03, demonstrated desirable PK characteristics, leading to generation of ketones and excellent safety and tolerability. Will be further investigated in a Phase 3 study in mild to moderate AD

Singapore, 30 July 2020 – Cerecin, a biopharmaceutical company focused on therapeutics to improve brain health, announced that the company presented two posters on its ketogenic drug *tricaprilin* being investigated for treatment of Alzheimer's disease (AD) at the Alzheimer's Association International Conference® (AAIC 2020) which was held virtually on 29 July.

In one poster, titled “*Development of tricaprilin, a ketogenic drug for Alzheimer's disease*”, Cerecin's Chief Medical Officer, Dr Judith Walker, presented details on the characterisation of two new formulations of the investigational drug *tricaprilin*, AC-SD-01 and AC-SD-03. Multiple formulations of *tricaprilin* were developed and tested in vitro, in vivo and in human studies to assess pharmacokinetics (PK), safety and tolerability. AC-SD-01 and AC-SD-03 both showed desirable PK characteristics, leading to generation of ketones and excellent safety and tolerability, when administered in doses of 20g *tricaprilin* after a meal in both Caucasians and Asians. Furthermore, in a separate study, *tricaprilin* 30g (as AC-SD-03) administered twice daily was well tolerated in a healthy elderly population, and generated excellent levels of ketosis. The AC-SD-03 formulation will be moved forward in development by Cerecin in a Phase 3 study in mild to moderate AD.

In a separate poster, titled “*The rat as a model for CER-0001 formulation development*”, Cerecin's Chief Scientific Officer, Dr Samuel Henderson, presented data from an investigation of the rat as a PK model of human formulations in order to accelerate the screening of formulations of *tricaprilin*. Previous studies have shown the formulation of *tricaprilin* can influence digestion and absorption of the drug, and ultimately the induction of ketosis, hence changes in formulation may influence clinical outcomes. The study found that the PK profiles of rats were qualitatively similar to those of humans and that using rats as a model to test formulations allows for faster, more cost-effective formulation development. Cerecin will conduct dissolution tests to add further knowledge to the development of proprietary formulations of *tricaprilin*.

The posters are available to view:

[Development of tricaprilin, a ketogenic drug for Alzheimer's disease](#)

Judith Anne Walker*, MD; Lars Nelleman*, MD; Lilian Chow*, MRDM; Samuel T Henderson**, PhD

[The rat as a model for CER-0001 formulation development](#)

Samuel T Henderson, PhD, Ameet Ambarkhane PhD, Bruce Morimoto, PhD, and Judith Walker, MD

Alzheimer's disease is an age-associated, neurodegenerative disease and the most common form of dementia. There is currently no cure and just a handful of approved treatments. According to a report published by Alzheimer's Disease International, the

number of people with dementia in Asia Pacific will increase from 23 million in 2015 to approximately 71 million by 2050.

ENDS

About Cerecin

Cerecin is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve brain health. Cerecin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of medium chain triglycerides. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and supported by two partners, Nestlé and Wilmar, one of the world's leading manufacturers and traders of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team and a highly differentiated portfolio, Cerecin is growing its global presence to serve the brain health needs of patients and people across the world.

For further information, please contact:

Thomas Harding/Khushboo Tanna/Nicole Ang

cerecin@spurwingcomms.com

© 2020 Cerecin AC-20-890 10/20